close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.165 +0.035 (+1.64%)
Streaming Delayed Price Updated: 3:30 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
38 39 Next >
News headline image
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Why Is Cassava Sciences (SAVA) Stock Up 10% Today? ↗
Cassava Sciences has completed part of an important Alzheimer’s disease treatment trial. Here's why SAVA stock may rise even more soon. 
Via InvestorPlace
$100 Invested In Cassava Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Cassava Sciences: Q3 Earnings Insights ↗
Cassava Sciences (NASDAQ:SAVA) reported its Q3 earnings results on Monday, November 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Is Anavex Life Sciences a Buy? ↗
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
News headline image
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds. 
Via Benzinga
News headline image
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022 ↗
After getting knocked down by controversy this year, can any of these seven corporate scandal stocks make a recovery? 
Via InvestorPlace
News headline image
Why Is Cassava Sciences (SAVA) Stock Up Today? ↗
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Is the Stock Market Open on Election Day 2022? ↗
Investors are wondering if the stock market is open on Election Day this year as they seek out extra time to head to the polls! 
Via InvestorPlace
News headline image
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers ↗
SAVA stock is in the green after reporting earnings. The company also filed a lawsuit against short sellers, alleging misleading statements. 
Via InvestorPlace
News headline image
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
What the Latest Controversy Really Means for SAVA Stock ↗
SAVA stock continues to be dogged by controversy, but the risk/reward proposition for this biotech largely remains the same. 
Via InvestorPlace
News headline image
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Why Is Cassava Sciences (SAVA) Stock Down 10% Today? ↗
SAVA stock is in the red after a piece from Probes Reporter accused Cassava of being involved with two undisclosed SEC investigations. 
Via InvestorPlace
News headline image
A New Study Makes Cassava Sciences Stock an Interesting Buy ↗
With the biotech firm moving forward with an open-label study of its Alzheimer's treatment simufilam, SAVA stock is one to watch. 
Via InvestorPlace
News headline image
Cassava Sciences Announces Expansion of Leadership Team
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Short Interest Sector Focus: Healthcare Sector ↗
As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
News headline image
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SAVA Stock Alert: Cassava Sciences Extends Trial ↗
SAVA stock is in focus after Cassava announced that it would begin an open-label study of its investigational Alzheimer's drug, simufilam. 
Via InvestorPlace
News headline image
Cassava Sciences Announces Initiation of an Open-label Extension Study
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock ↗
It's easy to get mired in the controversy surrounding Cassava Sciences, but distracted SAVA stock traders might miss an opportunity. 
Via InvestorPlace
News headline image
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today